[ad_1]
New Drug ‘Reduces Hospital Admission Or Death From COVID-19 By 85%’ Manufacturer Claims
An antibody drug made by the pharmaceutical company GlaxoSmithKline (GSK) has been found to dramatically reduce COVID-19-related hospitalizations and deaths.
VIR-7831 is a new treatment for people with mild to moderate illnesses, and the study was stopped early due to its high level of success.
GSK, with its partner Vir Technology, is now seeking an emergency use authorization for intravenous treatment in the US and potentially the UK.
GSK Chief Scientific Officer Dr. Hal Barron said: “We are pleased that this unique monoclonal antibody has been able to bring such profound benefit to patients.
“We look forward to making VIR-7831 available to patients as soon as possible and continuing to explore its potential in other settings.”
Last week a trial using the drug in very ill hospital patients was halted due to lack of benefits.
